Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Kemp, A. H., Quintana, D. S., Gray, M. A., Felmingham, K. L., Brown, K., & Gatt, J. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.012 · Cited by 1,286
Cited by
Zhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models
Caddeo, S., Boffito, M., & Sartori, S. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00040 · Cited by 285
Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues
McCain, M. L., Agarwal, A., Nesmith, H. W., Nesmith, A. P., & Parker, K. K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.052 · Cited by 237
“Cardiotoxicity is a leading cause of market withdrawal for drugs in the United States [1,2].”
BackgroundIn vitro cardiac tissue models: Current status and future prospects
Mathur, A., Ma, Z., Loskill, P., Jeeawoody, S., & Healy, K. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.011 · Cited by 187
“During preclinical and clinical development, cardiotoxicity remains a major cause of failure, with high rates of post-approval withdrawal of medicines [2].”
BackgroundTzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
Metadata
- Authors
- Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 138
- Issue
- 3
- Pages
- 470-484
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1997218466
- Cited by
- 205
- References
- 17
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. https://app.cochat.ai/papers/10.1016/j.pharmthera.2013.03.005
- The paper
- Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R. (2013). Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2013.03.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.